ADMA BiologicsADMA -0.54%64 Gross Margin % is 70.53% as of Mar. 2026, which is 480% above its 10-year median of 12.17. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.04 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 729 Biotechnology companies, ADMA Biologics ranks better than 50.62% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ADMA Biologics had a gross margin of 70.53% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
ADMA Biologics Gross Margin % Related Terms
ADMA Biologics Gross Margin % Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA vs ZLAB, HRMY, STOK: Gross Margin % Comparison
For the Biotechnology subindustry, ADMA Biologics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
ADMA Biologics (ADMA) has a Gross Margin % of 70.53% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on ADMA Biologics and its competitors. This is 480% above median its historical median of 12.17. According to the industry distribution chart, ADMA Biologics ranks #360 out of 729 companies in the Biotechnology industry, placing it in the top 49.4%.
Is ADMA Biologics' Gross Margin % too high?
ADMA Biologics' current Gross Margin % of 70.53% is 480% above median its 10-year median of 12.17. The Biotechnology industry median Gross Margin % is 60.92. ADMA Biologics' value of 70.53% is 15.8% above this industry median. Based on the distribution chart, ADMA Biologics ranks #360 out of 729 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Gross Margin % compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #360 out of 729 companies for Gross Margin %. This puts ADMA Biologics in the upper half of its industry. The industry median Gross Margin % is 60.92. ADMA Biologics' value of 70.53% is 15.8% above this benchmark. While the company's 10-year median is 12.17 vs. the industry median of 60.92, ADMA Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 729 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current Gross Margin % of 70.53% is 15.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on ADMA Biologics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Gross Margin % is 70.53%, which is 480% above median its own 10-year median of 12.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.04, compared to a current price of $9.16 — trading 49.2% below its estimated fair value. The current Gross Margin % is 70.53%, which is 480% above median its 10-year median of 12.17 and 15.8% above the Biotechnology industry median of 60.92. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Gross Margin % is 70.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $9.16 is trading 49.2% below its estimated GF Value™ of $18.04.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Gross Margin %: 70.53% (480% above median its 10-year median of 12.17)
GF Value™: $18.04 vs. price of $9.16 (49.2% below fair value)
Industry Position: 15.8% above the Biotechnology median (#360 of 729)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
